

**KDOQI Clinical Practice Guidelines and Clinical
Practice Recommendations for Anemia in Chronic
Kidney Disease**

Tables	S1
Figures	S2
Abbreviations and Acronyms	S4
Work Group Membership	S7
KDOQI Advisory Board Members	S8
Foreword	S9
I. EXECUTIVE SUMMARY	S11
II. CLINICAL PRACTICE GUIDELINES AND CLINICAL PRACTICE RECOMMEN- DATIONS FOR ANEMIA IN CHRONIC KIDNEY DISEASE IN ADULTS	S16
1.1. Identifying Patients and Initiating Evaluation	S17
1.2. Evaluation of Anemia in CKD	S28
2.1. Hb Range	S33
3.1. Using ESAs	S54
3.2. Using Iron Agents	S58
3.3. Using Pharmacological and Nonpharmacological Adjuvants to ESA Treatment in HD-CKD	S71
3.4. Transfusion Therapy	S79
3.5. Evaluating and Correcting Persistent Failure To Reach or Maintain Intended Hb	S81
III. CLINICAL PRACTICE RECOMMENDATIONS FOR ANEMIA IN CHRONIC KID- NEY DISEASE IN CHILDREN	S86
1.1: Identifying Patients and Initiating Evaluation	S87
1.2: Evaluation of Anemia in CKD	S89
2.1: Hb Range	S90

3.1: Using ESAs	S93
3.2: Using Iron Agents.....	S99
3.3: Using Pharmacological and NonPharmacological Adjuvants to ESA Treatment in HD-CKD.....	S105
3.4: Transfusion Therapy	S106
3.5: Evaluating and Correcting Persistent Failure To Reach or Maintain Intended Hb Level	S107
IV. CLINICAL PRACTICE RECOMMENDATIONS FOR ANEMIA IN CHRONIC KID- NEY DISEASE IN TRANSPLANT RECIPIENTS	S109
V. APPENDIX 1: METHODS OF EVIDENCE REVIEW AND SYNTHESIS	S117
Work Group Biographies	S126
Acknowledgments	S131
References	S132

KDOQI Disclaimer

SECTION I: USE OF THE CLINICAL PRACTICE GUIDELINES AND CLINICAL PRACTICE RECOMMENDATIONS

These Clinical Practice Guidelines (CPGs) and Clinical Practice Recommendations (CPRs) are based upon the best information available at the time of publication. They are designed to provide information and assist decision-making. They are not intended to define a standard of care, and should not be construed as one. Neither should they be interpreted as prescribing an exclusive course of management.

Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health-care professional making use of these CPGs and CPRs is responsible for evaluating the appropriateness of applying them in the setting of any particular clinical situation. The recommendations for research contained within this document are general and do not imply a specific protocol.

SECTION II: DEVELOPMENT PROCESS

The National Kidney Foundation makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional or business interest of a member of the Work Group.

Specifically, all members of the Work Group are required to complete, submit and sign a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest. All affiliations are published in their entirety at the end of this publication in the Biographical Sketch section of the Work Group members.

In citing this document, the following format should be used: National Kidney Foundation. *KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease*. Am J Kidney Dis 47:S1-S146, 2006 (suppl 3).

Support for the development of the KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease was provided by Amgen, Inc.



The National Kidney Foundation gratefully acknowledges the support of Amgen, Inc. as the founding and principal sponsor of KDOQI.

Tables

Table 1.	Key Differences Between Current Guidelines (KDOQI Anemia 2006) and Previous Anemia Guidelines (KDOQI 2000 and EBPG 2004)	S15
Table 2.	Relationship Between Hb Level and Kidney Function	S18
Table 3.	Relationship Between Hct and Kidney Function.....	S19
Table 4.	Prevalence of Anemia by Level of Kidney Function.....	S20
Table 5.	Difference in Hb and Hct From Reference by Category of C_{Cr}	S20
Table 6.	Difference in Hb and Hct From Reference According to Category of BSA and Normalized eGFR	S21
Table 7.	Hb for Males by Race/Ethnicity and Age: United States, 1988 to 1994.....	S24
Table 8.	Hb for Females by Race/Ethnicity and Age: United States, 1988 to 1994	S25
Table 9.	Normal Increase in Hb Levels Related to Long-Term Altitude Exposure	S26
Table 10.	Maximum Hb Cutoff Values for Anemia in Pregnancy	S27
Table 11.	Adjustment to Hb for Smoking by Number of Packets per Day.....	S27
Table 12.	RCTs Examining Effects of Distinct Hb Targets/Levels on Key Clinical Outcomes in the HD-CKD and PD-CKD Populations	S34
Table 13.	RCTs Examining Effects of Distinct Hb Targets/Levels on QOL in the HD-CKD and PD-CKD Populations.....	S36
Table 14.	Non-CVD/Mortality AE Rates in RCTs Examining Distinct Hb Targets/Levels in HD-CKD and PD-CKD Populations: ESA versus ESA	S38
Table 15.	Non-CVD/Mortality AE Rates in RCTs Examining Distinct Hb Targets/Levels in the HD-CKD and PD-CKD Populations: ESA versus Placebo	S40
Table 16.	Effects of Distinct Hb Targets/Levels on Key Clinical Outcomes in the ND-CKD Population	S41
Table 17.	RCTs Examining Effects of Distinct Hb Targets/Levels on QOL in the ND-CKD Population	S42
Table 18.	Non-CVD/Mortality AE Rates in RCTs Examining Distinct Hb Targets/Levels in the CKD Population	S43
Table 19.	RCTs Examining Effects of Distinct Hb Targets/Levels on Exercise Capacity in the HD-CKD and PD-CKD Populations	S44
Table 20.	Target Hb Levels in the HD-CKD and PD-CKD Populations.....	S45
Table 21.	Target Hb Levels in the ND-CKD Population.....	S48
Table 22.	Anemia Management Protocol Information for Initial Anemia Management Used in ESA RCTs	S56
Table 23.	RCTs for Ferritin and TSAT Targets in the HD-CKD Population	S60
Table 24.	Value of Baseline Ferritin for Assessing Likelihood of Response to IV Iron Therapy in the HD-CKD Population	S61
Table 25.	Value of Ferritin in Assessing Iron Storage Excess or Deficiency.....	S61
Table 26.	Value of Baseline TSAT for Assessing Likelihood of Response to IV Iron Therapy in the HD-CKD Population	S62
Table 27.	Value of Baseline CHR for Assessing Likelihood of Response to IV Iron Therapy	S62
Table 28.	Mean Monthly Dose of Iron in Adult Prevalent HD-CKD Patients on ESA Therapy....	S63
Table 29A.	Comparative RCTs of IV versus PO Iron Administration and Efficacy of Anemia Management in the HD-CKD and PD-CKD Populations	S65
Table 29B.	Comparative RCTs of IV versus PO Iron Administration and Efficacy of Anemia Management in the ND-CKD Population	S65
Table 30.	Comparative RCTs of PO Iron Administration versus Placebo/Control and Efficacy of Anemia Management in the HD-CKD and PD-CKD Populations	S66
Table 31.	Serious AEs of Iron Agents in Patients Naïve to Tested Iron Agent (N > 100)	S66
Table 31A.	IV versus PO Iron Agents in the HD-CKD and PD-CKD Populations	S67

Table 31B.	IV versus PO Iron Agents in the ND-CKD Population	S67
Table 32.	RCTs Evaluating Effects of Treatment with IV L-Carnitine on Hb Levels and ESA Doses in the HD-CKD Population.....	S72
Table 33.	Use of L-Carnitine as an Adjuvant to ESA Treatment in the HD-CKD Population.....	S73
Table 34.	RCTs Evaluating Effects of Treatment With IV Ascorbic Acid on Hb Levels and ESA Doses in the HD-CKD Population	S74
Table 35.	Use of Ascorbic Acid as an Adjuvant to ESA Treatments in the HD-CKD Population.....	S74
Table 36.	RCTs Evaluating Effects of Treatment With IM Androgens on Hb Levels in the HD-CKD Population	S75
Table 37.	Use of Androgens as an Adjuvant to ESA Treatment in the HD-CKD Population.....	S76
Table 38.	Published Experience in Patients With Anemia, CKD, and a Preexisting Hematologic Disorder	S84
Table 39.	Hb Levels (g/dL) in Children Between 1 and 19 Years for Initiation of Anemia Workup.....	S88
Table 40.	Hb Levels (g/dL) in Children Between Birth and 24 Months for Initiation of Anemia Workup.....	S88
Table 41.	Literature Review of Anemia in Transplant CKD: Key Conclusions	S110
Table 42.	Prevalance of PTA by Duration of Posttransplantation Period	S112
Table 43.	Example of a Summary Table.....	S119
Table 44.	Systematic Review Topics and Screening Criteria	S120
Table 45.	Literature Search Yield of Primary Articles for Systematic Review Topics.....	S121
Table 45A.	Assessment of Study Applicability	S121
Table 46.	Details of First-Look Topics, Ovid Literature Searches, and Yield by Topic	S122
Table 46A.	Grades for Study Quality	S122
Table 47.	Evaluation of Studies of Prevalence	S123
Table 48.	Format for Guidelines.....	S123
Table 49.	Balance of Benefit and Harm	S124
Table 50.	Definitions of Grades for Quality of Overall Evidence	S124
Table 51.	Example of an Evidence Profile	S125

Figures

Figure 1.	Kidney Failure in the United States	S12
Figure 2.	Relationship Between Current and Previous Anemia Guidelines	S14
Figure 3.	Relationship Between Hb Level and eGFR	S21
Figure 4.	Relationship Between eGFR and Prevalence of Anemia as Defined by Differing Hb Levels for (A) Males and (B) Females.....	S21
Figure 5.	Prevalence of Anemia by CKD Stage	S22
Figure 6.	Relationship Between Level of Renal Function, Reflected by S_{Cr} Level or GFR, and Prevalence of Anemia, Defined at Different Hb Cutoff Levels, Among Patients under the Care of Physicians	S22
Figure 7.	Hb Percentiles by GFR in the Canadian Multicentre Longitudinal Cohort Study	S22
Figure 8.	Prevalence of Low Hb Level by Category of GFR in the Canadian Multicentre Longitudinal Cohort Study.....	S23
Figure 9.	Prevalence of Low Hb Level by eGFR in Patients with Diabetics Compared with the General Population	S23
Figure 10.	Changes in Hb Levels and eGFR Over 2 years in Adult Patients with CKD Stages 3 and 4 Not Treated with ESA	S23
Figure 11.	Distribution of Hb Levels in Adult Males and Females by Age Group.....	S26
Figure 12.	Distribution of Ferritin and TSAT Values by Age Group in Males and Females	S30

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.